Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Globe Newswire News Releases

Jun 01, 2024 17:10 ET
National Skills Champions are Honoured at the Skills Canada National Competition 2024, in Québec
Today, Skills/Compétences Canada (SCC) released the final medal results of the Skills Canada National Competition (SCNC) 2024, in Québec City. Over the past week, over 500 students and apprentices from across the country competed for the title of...
Jun 01, 2024 15:00 ET
First Federal Savings Bank and ICBA Offer Tips to Help Simplify the Homebuying Process
In recognition of National Homeownership Month, First Federal Savings Bank and the Independent Community Bankers of America (ICBA) are encouraging consumers to consult their local community banker about how to make the homebuying process simple,...
Jun 01, 2024 13:39 ET
QuidelOrtho (QDEL) Investors Who Suffered Substantial Losses After QDEL Reported Disastrous Q4 2023 Results, Terminated CEO, & Withdrew FDA Submission Should Contact Hagens Berman Before June 11, 2024
Hagens Berman urges QuidelOrtho Corporation (NASDAQ: QDEL) investors who suffered substantial losses to submit your losses now. Class Period: Feb. 18, 2022 – Apr. 1, 2024Lead Plaintiff Deadline: June 11, 2024Visit:...
Jun 01, 2024 13:02 ET
Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort
Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced longer follow-up data from the EGFRwt cohort and initial clinical efficacy data from the...
Jun 01, 2024 12:55 ET
Union members and allies mark Injured Workers’ Day in locations across Ontario
The Ontario Federation of Labour (OFL) was pleased to support several events across Ontario today, as injured workers and their allies marked Injured Workers’ Day in the province. “For decades, injured workers have been leading the fight for...
Jun 01, 2024 12:36 ET
Prospera Energy Inc. Announces 2023 Financial Results
Prospera Energy Inc. ("Prospera" or the "Corporation") (PEI: TSX-V; OF6A: FRA) 2023 was a transformational year for Prospera transforming to horizontal well technology in the Saskatchewan heavy-oil fields. Also, to initiate medium/light-oil...
Jun 01, 2024 10:00 ET
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today presented additional data from the Phase 1 dose escalation...
Jun 01, 2024 10:00 ET
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-smal
Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with previously treated PD-L1-positive metastatic non-small cell lung cancer treated with a...
Jun 01, 2024 10:00 ET
SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), announced today, that the Poster [#296] Clinical Update Related to the First-In-Human Trial of SYS6002 (CRB-701), A Next-Generation Nectin-4 Targeting Antibody Drug...
Jun 01, 2024 09:14 ET
Flash News: OKX Announces Position Tier Adjustments for TURBO/USDT Perpetual Futures Listing
OKX, a leading crypto exchange by trading volume and a leading Web3 technology company, has issued updates for June 1, 2024. OKX Announces Position Tier Adjustments for TURBO/USDT Perpetual Futures ListingIn a continuous effort to enhance...
Jun 01, 2024 09:00 ET
ClearPoint Neuro Announces Full Market Release of SmartFrame OR™ and ClearPoint PRISM® 3T Laser Therapy System
ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announces full market release of its SmartFrame OR platform and ClearPoint...
Jun 01, 2024 09:00 ET
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment...
Jun 01, 2024 08:15 ET
FSLY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Fastly, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Fastly, Inc. (NYSE: FSLY) securities between February 15, 2024 and May 1, 2024, both dates inclusive (the “Class Period”), have until July 23, 2024 to seek appointment as...
Jun 01, 2024 08:15 ET
Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting
Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the...
Jun 01, 2024 08:05 ET
Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting
Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the...
Jun 01, 2024 08:00 ET
CryptoHeap Targets Top Position in Crypto Staking Industry Before Bull Run Concludes
CryptoHeap, an innovative leader in cryptocurrency staking services, today announced its ambitious goal to become the top crypto staking platform as the current bull run continues. This strategic push aims to position CryptoHeap at the...
Jun 01, 2024 08:00 ET
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response Data were presented at ASCO 2024, where Immunocore also...
Jun 01, 2024 08:00 ET
Kaskela Law LLC Announces Shareholder Investigation of WideOpenWest, Inc. (NYSE: WOW) and Encourages Investors to Contact the Firm
Kaskela Law LLC announces that it is investigating WideOpenWest, Inc. (NYSE: WOW) on behalf of the company’s shareholders. WideOpenWest shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) for...
Jun 01, 2024 08:00 ET
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today shared new clinical data from its ongoing KT-253 Phase 1 trial....
Jun 01, 2024 08:00 ET
Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024
Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company pioneering the design and development of a new class of custom-built protein drugs known as DARPin therapeutics, today...